Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Australian Red Cross Blood Service

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, safety, efficacy, and timely availability of therapeutic goods, such as medicines, medical devices, and blood products, in Australia. This legislation addresses the gap in ensuring that therapeutic goods available to consumers meet the necessary standards and are safe for use. The Act is overseen by the Australian Parliament, with the overarching policy objective of protecting public health by regulating therapeutic goods. In this instance, the Act empowers the Secretary to revoke the licence of a manufacturer of therapeutic goods when certain conditions are met. This power was exercised in the case of the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, which had its licence revoked at the request of the manufacturer itself. This revocation pertains specifically to the Blood Donor Centre Noarluanga, operating under Licence No. MI-25082005-LI-000863-1, at the Noarluanga Services Pre Admission Clinic, Noarluanga Centre SA 5168.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, importation, exportation, advertising, and sponsorship of therapeutic goods within Australia. This includes pharmaceutical products, medical devices, and biological products. The Act encompasses a broad range of entities such as manufacturers, wholesalers, importers, and sponsors, requiring them to comply with stringent regulations to ensure the safety, quality, and efficacy of therapeutic goods. The Act applies on a national level, extending its jurisdiction across all states and territories of Australia, thereby unifying the regulatory framework for therapeutic goods. However, certain exclusions exist, such as over-the-counter homeopathic products and products used solely for research purposes, which may not be fully regulated under this Act. The scope of the Act can be extended or restricted through subordinate instruments, which provide detailed guidelines and specifications on the regulation of therapeutic goods. The revocation of a manufacturer's licence, as evidenced by the notice issued under paragraph 41(1)(d) of the Act, is a demonstration of the regulatory authority's enforcement capabilities, ensuring compliance and maintaining public health standards.

Key Provisions

The Therapeutic Goods Act 1989 includes a provision under section 41(1)(d) that allows the Secretary to revoke a manufacturer's licence for therapeutic goods. In this particular case, the Secretary has exercised this power and revoked the licence held by the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society. Specifically, the licence for the Blood Donor Centre in Noarlunga, with the licence number MI-25082005-LI-000863-1, has been revoked. This revocation was carried out at the request of the manufacturer itself, which means that the Australian Red Cross Blood Service agreed to the cancellation of their manufacturing licence. Under the Therapeutic Goods Act 1989, the revocation of a licence to manufacture therapeutic goods imposes specific obligations on the parties involved. The manufacturer, in this case, the Australian Red Cross Blood Service, must cease all activities related to the manufacture of therapeutic goods as soon as the revocation notice is issued. This includes halting production, distribution, and any other activities related to the manufacture of therapeutic goods. Additionally, the manufacturer must ensure that all remaining stock is appropriately managed and that any ongoing processes are wound down in compliance with the Act's requirements. Failure to comply with the provisions of the Therapeutic Goods Act 1989, including the revocation of a licence, can result in various legal consequences. For example, continuing to manufacture or distribute therapeutic goods after a licence has been revoked is considered an offence. Such actions can lead to civil penalties, criminal charges, or both, depending on the severity of the breach. The maximum penalties for these offences can be significant, potentially including substantial fines and imprisonment, reflecting the importance of adhering to the regulatory framework governing therapeutic goods in Australia. The Therapeutic Goods Act 1989 also outlines specific penalties for breaches related to the manufacture of therapeutic goods. For instance, individuals or entities found guilty of manufacturing therapeutic goods without a valid licence can face criminal penalties, including fines that can reach up to $500,000 for individuals and $2.5 million for corporations, as well as imprisonment terms that may extend up to five years for individuals and seven years for corporations. These stringent penalties underscore the seriousness with which the Act treats violations of its provisions and the importance of compliance to ensure public health and safety.